“What children want and what they do”, a real life study of how long children inhale their asthma medication correctly in the home situation, monitored with homemade video clips with the iPad®.

“What children want and what they do: a real life study of the consistency and sustainability of the inhalation technique monitored with homemade video clips”.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20232

Enrollment

Registered

2014-03-17

Start date

2014-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Making a video clip of the inhalation technique using the iPad with the Fluticasone Diskus and Beclometasone Autohaler once a day during a period of one month

Eligibility

Inclusion criteria

Inclusion criteria: - Clinical history of asthma symptoms. - Age 6 through 18 years. - Children who are starting with inhaled corticosteroid medication or have the age and maturity to switch their inhaled corticosteroid medication to Diskus® or Autohaler®. - Ability to perform inhalation technique after instruction with Diskus® and Autohaler®. - Ability to record and send video clips of inhalation technique with an iPad®.

Exclusion criteria

Exclusion criteria: - Children who used or had been trained before with Diskus or Autohaler®. - Other cardiac or pulmonary comorbidity

Design outcomes

Primary

Measure	Time frame
Differences in sustainability of inhalation technique of Diskus® and Autohaler® in the home situation. This will be measured with the inhalation checklist for the Diskus® and Autohaler®. Endpoint will be the difference in score for the critical errors between both devices in the home situation.	—

Secondary

Measure	Time frame
• Differences in sustainability of inhalation technique between Flixotide Diskus® and Qvar Autohaler®, scored with the inhalation checklist, as demonstrated in the hospital with inhalation technique as videotaped in the home. Endpoint will be the difference in score for critical errors between inhalation technique demonstrated in the hospital with inhalation technique as videotaped in the home. • Difference in device preference in children at visit 1 and 2 measured with the self administered questionnaire for device preference. The endpoint will be the difference in outcomes for preference of device attributes between visit 1 and 2. • Difference in what determines the choice of device for a child at visit 1 and 2 measured with the self made questionnaire for importance and satisfaction of device attributes. The endpoint will be the difference in outcomes for importance and satisfaction of device attributes between visit 1 and 2. • Difference in device preference of the NP at visit 1 and 2 before and after the use of the Inhalation manager®. The endpoint will be the difference for device preference before and after using the Inhalation manager®.	—

Measure

Time frame

• Differences in sustainability of inhalation technique between Flixotide Diskus® and Qvar Autohaler®, scored with the inhalation checklist, as demonstrated in the hospital with inhalation technique as videotaped in the home. Endpoint will be the difference in score for critical errors between inhalation technique demonstrated in the hospital with inhalation technique as videotaped in the home. • Difference in device preference in children at visit 1 and 2 measured with the self administered questionnaire for device preference. The endpoint will be the difference in outcomes for preference of device attributes between visit 1 and 2. • Difference in what determines the choice of device for a child at visit 1 and 2 measured with the self made questionnaire for importance and satisfaction of device attributes. The endpoint will be the difference in outcomes for importance and satisfaction of device attributes between visit 1 and 2. • Difference in device preference of the NP at visit 1 and 2 before and after the use of the Inhalation manager®. The endpoint will be the difference for device preference before and after using the Inhalation manager®.

—

Contacts

Public ContactA. Kolk, van der

Haaksbergerstraat 55

a.vanderkolk@mst.nl0031(0)534872310

Outcome results